SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
HuMAB companies
An SI Board Since May 2000
Posts SubjectMarks Bans
1022 55 0
Emcee:  nigel bates Type:  Unmoderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
647COMPREHENSIVE ANNUAL ANTIBODY COVERAGE OF DISCOVERY, DEVELOPMENT, DEAL-MAKING &atnsaf-5/15/2004
646Avidex and Active Biotech Enter Collaboration to Develop Fusion Proteins CombiniIcebrg-5/13/2004
645not much info there. sounds like any of 50 applications from other companies inscaram(o)uche-5/6/2004
644<i>Don't know how interesting this might be, so parking for possible cnigel bates-5/4/2004
643"...Management indicated that Amgen's pipeline candidate AMG-162 (osteonigel bates-4/30/2004
642Back in the old days (or year 2000 to be exact) Abgenix bought IntraImmune TheraIcebrg-4/26/2004
641[InNexus -- cell-penetrating "super antibodies"] newscientist.com Chtuck-4/26/2004
640[Cloned transgenic farm animals produce a bispecific antibody for T cell-mediatetuck-4/23/2004
639InNexus Files for a Significant Expansion to its Intellectual Property for Antibnigel bates-4/15/2004
638Lilly to Evaluate GlycoFi's Glycoprotein Production Platform Thursday April Icebrg-4/8/2004
637XTLbio Announces Grant of HCV Human Monoclonal Antibody Patent Patent Covering nigel bates-4/8/2004
636That's the way that I'd lean. RANK was a preclinical project at IMNX, yscaram(o)uche-3/27/2004
635According to CAT's IR, AMG 162 isn't one of their mAbs.nigel bates-3/26/2004
634I can't either. However, I think RANKL was an Immunex target... and as OPG nigel bates-3/24/2004
633Nigel >>Any idea whose mAB it is ?>> No, I don't know and can&Icebrg-3/24/2004
632Amgen seems to have put some emphasis on AMG 162 in its recent presentation. Anigel bates-3/24/2004
631Millennium Announces FDA Selection of MLN2704 for Continuous Marketing ApplicatiIcebrg-3/17/2004
630Freebie Nature link on ion channels (thanks, Tuck) - nature.com - contains snigel bates-3/12/2004
629More or less on topic is fine by me. Am I right in thinking SGEN have made up a nigel bates-3/10/2004
628More or less on topic as some of the programs discussed involve humanized antibotuck-3/10/2004
627Erik, I think that anti-CTLA-4 is valuable play, and MEDX may have here somethiMiljenko Zuanic-3/7/2004
626DOMANTIS EXPANDS BROAD ANTIBODY PATENT POSITION New US Patent & European Panigel bates-3/6/2004
625Miljenko Sorry, no ideas at all. I just happened to notice the abstract. I had Icebrg-3/6/2004
624This is ABGX antibody. Do you know did PFE completed PI? Idea for future? Thnx,Miljenko Zuanic-3/5/2004
623CP-675,206 anti-CTLA4 antibody clinical candidate enhances IL-2 production in caIcebrg-3/5/2004
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News